256 related articles for article (PubMed ID: 37334353)
1. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
Xu Y; Li Z; Wu S; Guo L; Jiang X
Front Immunol; 2023; 14():1180170. PubMed ID: 37334353
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Liu J; Liu W; Lin F; Shi N
Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
[TBL] [Abstract][Full Text] [Related]
5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Kang Q; Chen JS; Yang H
Front Immunol; 2022; 13():1021537. PubMed ID: 36300119
[TBL] [Abstract][Full Text] [Related]
7. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.
Aljefri YE; Ghaddaf AA; Alkhunani TA; Alkhamisi TA; Alahmadi RA; Alamri AM; Alraddadi AA
Dermatol Ther; 2022 Jul; 35(7):e15544. PubMed ID: 35499185
[TBL] [Abstract][Full Text] [Related]
9. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
J Am Acad Dermatol; 2023 Jan; 88(1):29-39. PubMed ID: 35820547
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
[TBL] [Abstract][Full Text] [Related]
11. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.
Tsiogkas SG; Karamitrou EK; Grammatikopoulou MG; Zafiriou E; Bogdanos DP
Curr Med Res Opin; 2024 Feb; 40(2):155-163. PubMed ID: 37997745
[TBL] [Abstract][Full Text] [Related]
13. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
Kingston P; Blauvelt A; Strober B; Armstrong AW
J Psoriasis Psoriatic Arthritis; 2023 Oct; 8(4):156-165. PubMed ID: 38188537
[TBL] [Abstract][Full Text] [Related]
14. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Warren RB; Zhong Y; Zhuo J; Cichewicz A; Kadambi A; Junqueira D; Westley T; Kisa R; Daamen C; Augustin M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2839-2857. PubMed ID: 37801281
[TBL] [Abstract][Full Text] [Related]
15. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
16. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
[TBL] [Abstract][Full Text] [Related]
18. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
[TBL] [Abstract][Full Text] [Related]
19. Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Toth OAS; Meldola PF; Machado PG; Chiarelli GFC; Schnorrenberger E; Kracik JLS; de Carvalho CC; Guzatti JVL; Mease PJ
J Drugs Dermatol; 2024 Feb; 23(2):67-73. PubMed ID: 38306122
[TBL] [Abstract][Full Text] [Related]
20. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW; Park SH; Patel V; Hogan M; Wang WJ; Davidson D; Chirikov V
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2589-2603. PubMed ID: 37525000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
